In Cancer Biology,
Context Matters
Uncover immunotherapy biomarkers by visualizing the tumor microenvironment in context
We’ve rebranded some of our products, learn more ›
CODEX® is now PhenoCycler, Phenoptics™ is now Phenolmager.
Unmet Need in Cancer Immunotherapy
Despite the progress we’ve made in cancer immunotherapy, response rates continue to remain in the 20 to 30% range. There’s a need for biomarkers that can accurately predict response to treatment.
Understanding Cancer-Immune Biology
Immunotherapy treatments rely on the activation of the immune system to fight and kill tumor cells. The key to understanding more about tumor-immune biology lies in studying the complexity of the tumor microenvironment.
Transforming Your Approach to Cancer Biomarker Discovery
Multispectral Imaging enables the discovery of biomarker signatures from a single FFPE tissue section, while preserving the spatial context of the tumor microenvironment.
Visualize
See how cells organize and interact in the tumor microenvironment
Quantify
Shift the paradigm from subjective IHC measurements to quantitative, reproducible multiplex imaging
Predict
Reliably predict immunotherapy response and disease progression through novel biomarker signatures
Spatial Phenotypic Signatures - Predicting Immunotherapy Response
A New Biomarker Class in the Tumor Microenvironment
Spatial Phenotypic Signatures (SPS) measure the
Interactions and Cell Densities
Of Tumor and Immune Cells
Of Tumor and Immune Cells
in the tumor microenvironment.
Measuring Spatial Phenotypic Signatures
Spatial Phenotypic Signatures can be
accurately measured with
accurately measured with
MULTIPLEX IMAGING
Better Predictive Capabilities and Reproducibility
A multi-institutional study found that mIF had
Higher Predictive Accuracy
than PD-L1 IHC and genomic biomarkers.
Saving Precious Time and Tissue Samples
With multiplex imaging, you can:
Analyze dozens of cell phenotypes and their spatial interactions from a
SINGLE FFPE TISSUE SECTION
Process
25 to 30 SAMPLES PER DAY
Oncology Experts Discover Spatial Phenotypic Signatures with Multiplex Imaging
Standardization Efforts
The value of Spatial Phenotypic Signatures in translational and clinical research relies on a standardized and reproducible workflow.
MITRE: First Multi-Site mIF Standardization Study
6 leading institutions, across academia and pharma, established the inter- and intra-site reproducibility of the Phenoptics multiplex imaging workflow.
Validating Multiplex Imaging Panels for PD-L1 Testing
Studies by pathologists at Queen’s University show high concordance between DAB IHC and multispectral imaging panels for profiling immunotherapy biomarkers.
Bringing Multiplex Imaging to the Clinic
Dr. Joe Yeong, Immunopathologist at the Singapore General Hospital predicts that multiplex imaging is poised to transform the cancer biomarker landscape.
